poisar

Stock

Autolus Therapeutics plc AUTL

$2.13-4.09%

Overview

AUTL market data

Price History

AUTL price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$1.08
Diluted earnings per share over the trailing twelve months.
Beta
2.17
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-312.0%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1.18 – $2.50
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $564.3M · P/B 2.94 · P/S 6.09.

Company News

10 captured
Autolus Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 11, 2026, 4:57 PM
8-K filing — Autolus Therapeutics plc (AUTL)SEC EDGAR · Aug 11, 2026, 11:33 AM
Autolus Therapeutics Affirms FY2026 Sales Guidance of $140.000M-$150.000M vs $136.669M EstBenzinga · Aug 11, 2026, 11:01 AM
Autolus Therapeutics Q2 EPS $(0.15) Beats $(0.23) Estimate, Sales $45.689M Beat $34.016M EstimateBenzinga · Aug 11, 2026, 11:00 AM
HC Wainwright & Co. Reiterates Buy on Autolus Therapeutics, Maintains $10 Price TargetBenzinga · Aug 3, 2026, 5:25 PM
CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On MondayBenzinga · Aug 3, 2026, 2:00 PM
Autolus Therapeutics shares are trading higher after the company reported preliminary Q2 AUCATZYL sales results. Also, the company raised its FY26 sales guidance.Benzinga · Aug 3, 2026, 12:52 PM
Autolus Therapeutics Reports Preliminary Q2 AUCATZYL Sales Of ~$45M; Raises FY2026 Sales Guidance From $120M-$135M To $140M-$150MBenzinga · Aug 3, 2026, 11:20 AM
Autolus Therapeutics to Participate in Upcoming Investor ConferencesGlobenewswire Inc · May 27, 2026, 11:15 AM
Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On MondayBenzinga · May 18, 2026, 4:35 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock